Amryt Pharma plc
http://www.amrytpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amryt Pharma plc
Amryt Optimistic For Year Ahead Despite Filsuvez CRL Setback
The rare disease firm hopes continued growth of key products Myalept and Mycapssa will bolster 2022 revenues as it contends with a US regulatory delay for Filsuvez.
Finance Watch: Financial Market Turmoil Ends Amicus SPAC Deal For Gene Therapy Spinout
Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.
Krystal Sees Success With Topical Gene Therapy In Debilitating Rare Skin Disorder
A regulatory filing for Vyjuvek in the US is targeted for the first half of 2022 following the positive results of a Phase III trial, positioning Krystal for its first commercial launch.
Biotechs Choosing Brazil For Drug Development And Early Sales
Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Aegerion Pharmaceuticals, Inc.
- Amryt Pharma Holdings Limited
- Birken GmbH
- Birken AG
- Chiasma, Inc.
- Sompharmaceuticals